slides · global inventory
Table
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 60,557
Current window 43,441-43,470
Pages 2,019
Rows per page 30
Component
43,441-43,470 of 60,557
06
The slide uses a standard pharmaceutical pipeline table format.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations Beat · Solution1 hit
09
Includes a mechanism of action diagram, a market data table, and a comparison of current therapy limitations.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
11
Includes both a longitudinal line chart of IRAK4 reduction and a grouped bar chart with a summary table for cytokine inhibition.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
15
The slide includes a disclaimer regarding the non-head-to-head nature of the comparison.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
17
The slide includes a disclaimer regarding the non-head-to-head nature of the comparison.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
18
The slide highlights a favorable safety profile with no serious adverse events (SAEs) or drug-related infections.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
22
Includes a table of prevalence/incidence for various indications and a diagram of the JAK-STAT signaling pathway.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
24
The slide uses a process flow diagram to illustrate the dose escalation (0.05 to 0.40 mg/kg) leading to MTD/RP2D expansion into four specific patient cohorts.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
25
The table displays adverse events occurring in 2 or more patients. Data includes patient counts and percentages for both 'All' and 'Related' adverse events.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
26
Includes a line chart showing plasma concentration over time and a table summarizing PK parameters (Cmax, AUClast, Vd, CL, t1/2).Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
33
Includes three dose-response curves and a comparative table of clinical stage and potency metrics.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
35
Includes a visual representation of the dose escalation study design and a detailed table of patient baseline characteristics.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
36
The slide combines a biological mechanism diagram with clinical trial data (table and line chart) to validate the drug's mechanism of action.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
09
Details the dosing schedule (13 days) and specific sampling days for buccal cells, skin, and platelets across three dose levels.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
11
The slide outlines the methodology for a clinical trial, specifically focusing on the 28-day treatment schedule and cohort details.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
17
The slide highlights the unique 'Protein replacement' approach of Nomlabofusp compared to other modalities like Mitochondrial Oxidative Stress Modifiers, Gene Expression Regulators, Pathway Modifiers, and Gene Therapy.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
26
The slide details the dosing schedule (13 days) and specific sampling days for buccal cells, skin, and platelets across three dose cohorts (25mg, 50mg, 100mg).Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
28
The table displays n (%) for categorical variables and descriptive statistics (mean, SD, median, range) for age.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
29
MAD likely stands for Multiple Ascending Dose.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
33
The slide outlines a 28-day treatment schedule with specific administration days highlighted in green.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
36
The slide highlights that demographics are similar between Phase 1 and Phase 2 trials.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
37
Data presented as n, mean (SD), median, Q1/Q3, and min/max.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
08
The chart shows a stacked bar breakdown of U.S. vs EU sales over 6 quarters.Legend Biotech | Results Presentation Deck | 15 slides · Legend Biotech
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
10
The slide uses a 3x4 grid structure to present key performance indicators and milestones.Lenovo | Results Presentation Deck | 18 slides · Lenovo
Conference presentation Investor relations Beat · KPI OverviewLoop · Logic Chain1 hit
13
The table includes both GAAP and non-HKFRS metrics, with year-over-year percentage changes.Lenovo | Results Presentation Deck | 18 slides · Lenovo
Conference presentation Investor relations Beat · Appendix1 hit
14
Lenovo | Results Presentation Deck | 18 slidesLenovo | Results Presentation Deck | 18 slides · Lenovo
Conference presentation Investor relations Beat · Appendix1 hit
15
Lenovo | Results Presentation Deck | 18 slidesLenovo | Results Presentation Deck | 18 slides · Lenovo
Conference presentation Investor relations Beat · Appendix1 hit
16
Lenovo | Results Presentation Deck | 18 slidesLenovo | Results Presentation Deck | 18 slides · Lenovo
Conference presentation Investor relations Beat · Appendix1 hit
17
The table reconciles 'As reported' figures to 'Non-HKFRS' figures by adjusting for fair value changes, amortization of intangible assets, and M&A related charges.Lenovo | Results Presentation Deck | 18 slides · Lenovo
Conference presentation Investor relations Beat · Appendix1 hit
08
Uses a checkmark/cross matrix to demonstrate competitive advantage.Limbach Holdings | Investor Presentation Deck | 28 slides · Limbach
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit